Characterization of the \textit{Plasmodium falciparum} and \textit{P. berghei} glycerol 3-phosphate acyltransferase involved in FASII fatty acid utilization in the malaria parasite apicoplast

Melanie J. Shears,1,2 James I. MacRae,3 Vanessa Mollard,1 Christopher D. Goodman,1 Angelika Sturm,1 Lindsey M. Orchard,4 Manuel Llinás,4 Malcolm J. McConville,5 Cyrille Y. Botté6* and Geoffrey I. McFadden1*†

1 School of BioSciences, University of Melbourne, VIC 3010, Australia.
2 Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, 21205, United States.
3 The Francis Crick Institute, Metabolomics, The Ridgeway, Mill Hill, London, NW7 1AA, United Kingdom.
4 Department of Biochemistry and Molecular Biology, Department of Chemistry and Center for Malaria Research, Pennsylvania State University, State College, University Park, PA, 16802, United States.
5 Department of Biochemistry and Molecular Biology, University of Melbourne, Melbourne, VIC 3010, Australia.
6 Apicolipid team, Institute for Advanced Biosciences UMR CNRS5309 INSERM U1209, Université Grenoble Alpes, Grenoble, France.

Summary

Malaria parasites can synthesize fatty acids via a type II fatty acid synthesis (FASII) pathway located in their apicoplast. The FASII pathway has been pursued as an anti-malarial drug target, but surprisingly little is known about its role in lipid metabolism. Here we characterize the apicoplast glycerol 3-phosphate acyltransferase that acts immediately downstream of FASII in human (\textit{Plasmodium falciparum}) and rodent (\textit{Plasmodium berghei}) malaria parasites and investigate how this enzyme contributes to incorporating FASII fatty acids into precursors for membrane lipid synthesis. Apicoplast targeting of the \textit{P. falciparum} and \textit{P. berghei} enzymes are confirmed by fusion of the N-terminal targeting sequence to GFP and 3′ tagging of the full length protein. Activity of the \textit{P. falciparum} enzyme is demonstrated by complementation in mutant bacteria, and critical residues in the putative active site identified by site-directed mutagenesis. Genetic disruption of the \textit{P. falciparum} enzyme demonstrates it is dispensable in blood stage parasites, even in conditions known to induce FASII activity. Disruption of the \textit{P. berghei} enzyme demonstrates it is dispensable in blood and mosquito stage parasites, and only essential for development in the late liver stage, consistent with the requirement for FASII in rodent malaria models. However, the \textit{P. berghei} mutant liver stage phenotype is found to only partially phenocopy loss of FASII, suggesting newly made fatty acids can take multiple pathways out of the apicoplast and so giving new insight into the role of FASII and apicoplast glycerol 3-phosphate acyltransferase in malaria parasites.

Introduction

Malaria is caused by \textit{Plasmodium} parasites, which have a complex life cycle involving multiple stages in the human and mosquito hosts (Greenwood \textit{et al.}, 2008; Aly \textit{et al.}, 2009). \textit{Plasmodium} parasites require fatty acids for membrane lipid synthesis and other essential activities, and possess both an endogenous fatty acid synthesis pathway and mechanisms for scavenging fatty acids from the host (Déchamps \textit{et al.}, 2010). The parasite fatty acid synthesis pathway is located in the apicoplast, a reduced plastid organelle homologous to chloroplasts of plants and algae (van Dooren and Striepen, 2013). As in chloroplasts and bacteria, the apicoplast harbours a dissociative, or type II fatty acid synthesis (FASII) pathway, which is intrinsically different to the FASI pathway of humans (Waller \textit{et al.}, 1998). This characteristic, and the assumption that FASII was essential in blood stage parasites, led to its promotion as a target for anti-malarial drugs, and considerable research was directed toward identifying FASII inhibitors.
(Shears et al., 2015). However, transcriptomic and genetic studies with the human malaria parasite *Plasmodium falciparum* and the rodent models *Plasmodium berghei* and *Plasmodium yoelii* subsequently overturned this assumption, with FASII enzymes found to be minimally expressed (Bozdech et al., 2003; Le Roch et al., 2003; Linás, 2006) and ultimately dispensable in blood stage parasites (Yu et al., 2008; Vaughan et al., 2009). These data not only indicated that FASII was invalid as a therapeutic target, but also that fatty acid scavenging was instead primarily responsible for supporting lipid synthesis at this stage. In *P. berghei* and *P. yoelii*, FASII was found to be essential for parasite development in the late liver stage, suggesting it might still be targeted for malaria prophylaxis (Yu et al., 2008; Vaughan et al., 2009). In *P. falciparum*, however, FASII was unexpectedly discovered to be essential for sporozoite development, precluding analysis of mutants in the liver stage and crucial validation of the pathway as a prophylactic target (van Schaijk et al., 2014). These unanticipated findings emphasized a need for further research into FASII, and raised questions about both the role of the pathway in parasite lipid metabolism and its actual potential as a target for malaria prevention.

Several hypotheses have been proposed to explain why FASII is essential at certain stages of the malaria parasite life cycle. FASII primarily produces the fatty acid myristate (C14:0) (Botté et al., 2013), which is predicted to be used for phospholipid synthesis because these make up the majority of parasite membranes (Déchamps et al., 2010). FASII also produces octanoylate (C8:0), but as this seems to only be essential for synthesis of lipoic acid for the apicoplast pyruvate dehydrogenase, itself a FASII enzyme, this function appears to be solely self-sustaining (Storm and Müller, 2012). Based on the observations that FASII null mutants arrest at replicative life stages and show reduced growth and organelle development in the preceding stage (Yu et al., 2008; Vaughan et al., 2009; Pei et al., 2010; Butler et al., 2011; Annoura et al., 2012; Nagel et al., 2013; van Schaijk et al., 2014), it has been proposed that FASII is required to supplement fatty acid scavenging and boost bulk membrane lipid synthesis (Yu et al., 2008). Alternatively, it has been hypothesized that FASII is required for synthesis of certain essential lipids that cannot be acquired from the host (Taran et al., 2009). As FASII null mutants in rodent models consistently show reduced expression of the liver stage marker merozoite surface protein 1 (MSP1), it was suggested that FASII may be needed for production of the glycosylphatidylinositol (GPI) anchor of the protein (Taran et al., 2009). This in turn sparked the hypothesis that *P. falciparum* may be reliant on FASII in the mosquito stages for synthesis of the GPI anchor of the circumsporozoite protein (CSP) or other essential surface proteins (van Schaijk et al., 2014), but so far there is no definitive experimental evidence to support or distinguish these hypotheses.

As in other organisms, malaria parasites are predicted to synthesize phospholipids and the lipid moieties of GPI anchors from a precursor known as phosphatidic acid (Déchamps et al., 2010). Phosphatidic acid is produced via a two-step pathway involving a glycerol 3-phosphate acyltransferase (G3PAT) and lysophosphatidic acid acyltransferase (LPAAT), which rely on conserved histidine and aspartate residues in a 'HX4D' motif (Heath and Rock, 1998) to catalyse the attachment of fatty acids to the first and second positions of glycerol 3-phosphate, respectively. *Plasmodium* parasites have been predicted to have two sets of these enzymes, one set in the apicoplast and another set in the endoplasmic reticulum (ER) (Santiago et al., 2004; Lindner et al., 2014). The identification of a putative mechanism for apicoplast fatty acid export (Ralph et al., 2004) indicates FASII can potentially contribute fatty acids to both of these pathways. To date, however, there have been relatively few studies to provide evidence for FASII fatty acids being used in phosphatidic acid synthesis in either organelle. The *P. falciparum* ER G3PAT has been characterized and uses a range of fatty acids including myristate (C14:0) (Santiago et al., 2004), providing suggestive data that FASII may provide substrates to this enzyme. The *P. yoelii* apicoplast G3PAT has also been characterized and its deletion found to phenocopy FASII null mutants in the late liver stage (Lindner et al., 2014), providing a more tangible link between the two pathways in this model. Surprisingly, however, the same study also found the predicted *P. yoelii* apicoplast LPAAT was localized to the ER, indicating the apicoplast pathway may differ from that in other plastid-bearing organisms and instead only produce the intermediate lysophosphatidic acid (Lindner et al., 2014). Therefore, although the apicoplast and ER acyltransferases are predicted to be integral for linking FASII with membrane lipid synthesis, their precise role in FASII fatty acid metabolism is yet to be elucidated.

In this study, we characterize the apicoplast G3PAT of *P. falciparum* (*Pf* apiG3PAT) and *P. berghei* (*Pb* apiG3PAT) to further explore how this enzyme contributes to FASII fatty acid metabolism. We confirm the apicoplast targeting and activity of *Pf* apiG3PAT and investigate residues in its predicted active site by targeted mutagenesis. We establish the dispensability of *Pf* apiG3PAT in the blood stage, and compare the phenotype of mutant and wild type parasites in both standard media and conditions that induce FASII activity to make additional inferences about fatty acid metabolism at this stage. Performing complementary studies in *P. berghei*, we verify the apicoplast localization of *Pb* apiG3PAT and demonstrate the enzyme is critical for parasite development in the late liver stage, consistent with findings for its *P. yoelii* homolog. We further show that the
Pb apiG3PAT deletion mutant phenocopies the *P. berghei* FASII null mutant phenotype in many respects, but not in the severity of the MSP1 expression defect, revealing novel insight into the role of the enzyme in lipid metabolism and the complex interplay between pathways for fatty acid metabolism in the apicoplast and ER.

**Results and discussion**

*Pf* apiG3PAT is targeted to the apicoplast and functions as a typical G3PAT

*Pf* apiG3PAT was initially implicated as a putative apicoplast protein on the basis of a predicted apicoplast targeting sequence at its N-terminus (Ralph *et al.*, 2004). Further *in silico* analysis of *Pf* apiG3PAT confirmed the presence of a putative apicoplast targeting sequence of 70 amino acids that contained a predicted signal peptide and predicted transit peptide as expected (Zuegge *et al.*, 2001; Foth *et al.*, 2003; Petersen *et al.*, 2011) (Supplementary Fig. 1).

To test if this putative apicoplast targeting sequence was functional, we generated the transgenic *Pf apiG3PAT1–70 gfp* parasite line, which expressed the predicted *Pf* apiG3PAT apicoplast targeting sequence fused to a C-terminal green fluorescent protein (GFP) reporter. Live fluorescence microscopy of blood stage *Pf apiG3PAT1–70 gfp* parasites revealed that GFP was directed to a discrete cellular compartment characteristic of the apicoplast (van Dooren *et al.*, 2005) in ring, trophozoite and schizont stage parasites (Fig. 1A). Immunofluorescence microscopy of *Pf apiG3PAT1–70 gfp* parasites confirmed GFP was targeted to the apicoplast by co-localization with the apicoplast marker, acyl carrier protein (ACP; Waller *et al.*, 2000) (Fig. 1B).

**Fig. 1.** *Pf* apiG3PAT has a functional apicoplast targeting sequence and rescues growth in a G3PAT-deficient mutant strain of *E. coli*.

**A.** Live fluorescence microscopy of *Pf apiG3PAT1–70 gfp* parasites shows the predicted *Pf* apiG3PAT apicoplast targeting sequence directs GFP to a discrete cellular compartment in rings, trophozoites and schizonts.

**B.** Immunofluorescence microscopy of *Pf apiG3PAT1–70 gfp* parasites using antibodies against GFP and the apicoplast marker ACP demonstrates the predicted *Pf* apiG3PAT apicoplast targeting sequence targets GFP to the apicoplast. DNA stained with DAPI. Scale 3 μm.

**C.** *Pf* apiG3PAT partially restores growth in a G3PAT-deficient mutant of *E. coli*, demonstrating it is active as a G3PAT. Bacteria were transformed with a vector encoding a His-tagged version of *Pf* apiG3PAT, the empty vector or *E. coli*G3PAT positive control. Western blot of bacterial extracts confirms expression of the tagged *Pf* apiG3PAT (expected mass of 47 kDa). D–E. Mutation of the conserved histidine or aspartate in the ‘HXxD’ motif of *Pf* apiG3PAT abolishes its ability to restore growth in the *E. coli* mutant. Bacteria were transformed with vectors encoding His-tagged versions of the histidine to alanine mutant (*Pf* apiG3PAT_H195A), aspartate to alanine mutant (*Pf* apiG3PAT_D200A), empty vector or *E. coli*G3PAT positive control. Western blot of bacterial extracts confirms expression of *Pf* apiG3PAT_D200A, but fails to detect *Pf* apiG3PAT_H195A, suggesting the conserved histidine may be required for correct folding or stability of the enzyme.
Having demonstrated that Pf apiG3PAT was active, we next sought to test whether, as in other characterized G3PAs (Ralph et al., 2004) and the presence of the ‘HX₄D’ catalytic motif characteristic of the enzyme class (Heath and Rock, 1998) (Supplementary Fig. 1). To test whether Pf apiG3PAT had the predicted activity, we employed an established complementation assay using the G3PAT-deficient plsB26 mutant strain of Escherichia coli (Bell, 1974). The plsB26 mutant has a defective G3PAT that renders it unable to grow in minimal media lacking glycerol unless complemented with a functional enzyme (Bell, 1974). To test Pf apiG3PAT for activity, we transformed mutant bacteria with a vector encoding a hexahistidine-tagged version of the protein (without the apicoplast targeting sequence), then monitored for growth on minimal media without glycerol in two separate experiments. As controls, we transformed bacteria with the empty vector or a positive control vector encoding a His-tagged version of the wild type E. coli G3PAT. Bacteria transformed with the Pf apiG3PAT vector grew markedly better than the empty vector control, and achieved approximately 60% of the growth observed for the positive control (Fig. 1C), consistent with findings for Py apiG3PAT (Lindner et al., 2014). Western blot analysis of extracts from transformed bacteria using anti-His antibodies also verified that the tagged Pf apiG3PAT was expressed and soluble as expected. This demonstrated that Pf apiG3PAT expression was sufficient to partially restore growth in the G3PAT-deficient bacterial mutant, confirming that Pf apiG3PAT was active as a G3PAT.

Having demonstrated that Pf apiG3PAT was active, we next sought to test whether, as in other characterized G3PAs (Heath and Rock, 1998; Lewin et al., 1999; Turnbull et al., 2001; Tamada et al., 2004), the conserved histidine and aspartate residues of the ‘HX₄D’ motif were important for catalysis. To investigate this, we individually mutated the conserved histidine and aspartate residues of Pf apiG3PAT to alanine, then tested the resultant proteins for their ability to rescue growth in the bacterial complementation assay. Bacteria transformed with the vector encoding the Pf apiG3PATH195A histidine to alanine mutant had the same residual growth rate as bacteria transfected with the empty vector control, suggesting the conserved histidine was required for Pf apiG3PAT activity (Fig. 1D). However, we were unable to detect this protein by Western blot analysis despite numerous attempts, and so could not exclude the alternate hypothesis that alteration of the residue had affected the expression, folding or stability of the protein. Bacteria transformed with the vector encoding the Pf apiG3PATOM200A aspartate to alanine mutant were similarly indistinguishable from the empty vector control, and in this case weak expression of the protein could be detected by Western blot analysis (Fig. 1E). These observations indicated that Pf apiG3PAT likely resembled characterized G3PAs in its reliance on the conserved histidine and aspartate of the ‘HX₄D’ active site motif for activity or folding, indicating the enzymes putatively share a common mechanism of catalysis.

Pf apiG3PAT is dispensable in asexual blood stage parasites

Having confirmed the apicoplast localization and activity of Pf apiG3PAT, we next sought to determine the requirement for the enzyme in blood stage parasites. Because we expected Pf apiG3PAT would primarily or exclusively use FASII fatty acids, we predicted that it would be dispensable in asexual blood stage parasites. To test this we used a double cross over homologous recombination strategy to disrupt the Pf apiG3PAT locus, inserting the human dihydrofolate reductase (hDHFR) drug resistance cassette into coding sequence to truncate the enzyme and eliminate the ‘HX₄D’ active site motif (Supplementary Fig. 2). Drug-resistant parasites were obtained from two independent transfections in the D10 wild type background, and the successful integration of the hDHFR cassette into the Pf apiG3PAT locus was confirmed by PCR for each line (Supplementary Fig. 2). We also attempted to transfect into the mosquito-transmissible NF54 wild type background on three separate occasions without success (data not shown). Proceeding with the two lines in the D10 background, we observed both Pf apiG3PAT (−) lines were viable and grew normally as determined by frequency of subculturing, suggesting Pf apiG3PAT was indeed dispensable for blood stage growth.

As we had employed a transfection strategy that relied on negative selection to eliminate wild type parasites rather than cloning by limiting dilution (Maier et al., 2006), we also sought to verify the disruption of the Pf apiG3PAT locus by whole genome sequencing of one line. This analysis again confirmed the successful integration of the hDHFR cassette into the Pf apiG3PAT locus, and although three single base changes were identified between the mutant line and the wild type parent across the entire genome, targeted PCR-based sequencing of these regions in the second Pf apiG3PAT (−) line revealed that they were not conserved (sequencing data deposited in NCBI Short Read Archive under accession number SRP071808, PCR data not shown). Therefore, we reasoned the ability to recover Pf apiG3PAT (−) parasites was not because of compensatory mutations or insertion of the selectable marker at other loci, and hence that Pf apiG3PAT activity was truly dispensable in blood stage parasites.

To investigate whether disruption of Pf apiG3PAT produced any subtle phenotype in the growth or development of blood stage parasites, one Pf apiG3PAT (−) line was selected for further characterization. First, to monitor
apicoplast development in the asexual blood stage cycle, we performed immunofluorescence microscopy using antibodies against the apicoplast marker ACP (Waller et al., 2000). No difference was observed between the \textit{Pf} \textit{apiG3PAT} (−) line and wild type parasites in apicoplast appearance in ring, trophozoite or schizont stages, indicating disruption of the enzyme did not impact apicoplast development in the blood stage (Fig. 2A). Transmission electron microscopy further confirmed this finding, with typical apicoplast ulrastructure and membrane organization observed in trophozoite stage parasites of both lines, and whorls of membrane seen in the apicoplast lumen in the \textit{Pf} \textit{apiG3PAT} (−) parasite as previously reported for wild type (Lemgruber et al., 2013) (Fig. 2B). Disruption of \textit{Pf} \textit{apiG3PAT} therefore had no appreciable impact on apicoplast development in blood stage parasites grown in standard culture conditions, indicating the enzyme was not required for apicoplast membrane synthesis and was either non-active or functionally redundant in this stage.

To investigate whether disruption of \textit{Pf} \textit{apiG3PAT} had any effect on parasite growth or cell cycle progression, the replication rate of synchronized parasites from the \textit{Pf} \textit{apiG3PAT} (−) and wild type line were compared using an established four day growth assay (Mitamura et al., 2000; Mi-Ichi et al., 2006). No difference was observed between \textit{Pf} \textit{apiG3PAT} (−) and wild type parasites in replication rate in standard culture conditions, with both lines found to increase in parasitemia between five and six fold per cycle (Fig. 3A). Similarly, no appreciable difference was detected between \textit{Pf} \textit{apiG3PAT} (−) and wild type parasites in the proportion of rings or trophozoites present each day of the assay (Supplementary Fig. 3), providing preliminary evidence that disruption of \textit{Pf} \textit{apiG3PAT} had no effect on either parasite growth or cell progression in the blood stage. This lack of growth phenotype was further supported by GC-MS analysis of magnetically isolated \textit{Pf} \textit{apiG3PAT} (−) and wild type infected red blood cells, which showed disruption of the enzyme had no significant affect on the overall fatty acid profile of parasite lipids (Fig. 3B and C, Supplementary Table 2). Together, these findings demonstrated that \textit{Pf} \textit{apiG3PAT} was dispensable in blood stage parasites in standard culture conditions, and suggested the enzyme did not normally contribute to bulk membrane lipid synthesis in this stage.

Last, as it has previously been reported that \textit{Pf} \textit{apiG3PAT} and FASII expression is up-regulated in \textit{P. falciparum ex vivo} isolates displaying a ‘starvation’ transcriptional response (Daily et al., 2007), we hypothesized that \textit{Pf} \textit{apiG3PAT} may be important in blood stage parasites in environments where exogenous fatty acids are limiting. To test this, we repeated the growth assay using lipid-depleted media containing only palmitate (C16:0) and oleate (C18:1), because these are the minimum fatty acid set required to support parasite growth, and the conditions were previously shown to also induce FASII activity (Botté et al., 2013). Again, no difference was observed between the \textit{Pf} \textit{apiG3PAT} (−) line and wild type in their fold replication per cycle in lipid-depleted conditions, with both lines failing to
increase in parasitemia after the first cycle (Fig. 3D). Furthermore, although the growth of \textit{Pf} apiG3PAT (−) and wild type parasites was clearly reduced in lipid-depleted media, both displayed normal cell cycle progression, indicating a low number of successful replication events had indeed taken place (Supplementary Fig. 3). Thus disruption of \textit{Pf} apiG3PAT caused no further reduction in growth in lipid-depleted media beyond that observed for wild type. This suggested that incorporation of FASII fatty acids into membrane lipid precursors in the apicoplast was not essential at this stage, and by extension, that these fatty acids were instead likely exported and utilized by other pathways.

\textit{Pb} apiG3PAT is targeted to the apicoplast and expressed in liver stage parasites

\textit{Pb} apiG3PAT shares strong sequence similarity with \textit{Pf} apiG3PAT and is likewise predicted to possess an apicoplast targeting sequence at its N-terminus (Supplementary Fig. 1). To verify that \textit{Pb} apiG3PAT is targeted to the apicoplast, we used a 3′ gene replacement strategy to generate the \textit{Pb} apiG3PAT \textit{ha gfp} transgenic line, which expressed the full-length protein fused to C-terminal hemagglutinin (HA) and GFP tags (Supplementary Fig. 4). We chose this approach as it resulted in the tagged protein being expressed from the endogenous promoter, and could therefore also provide information about when in the life cycle \textit{Pb} apiG3PAT was expressed. No GFP fluorescence was observed in blood stage parasites, oocysts or salivary gland sporozoites by live fluorescence microscopy, indicating \textit{Pb} apiG3PAT was not expressed at detectable levels in these stages (data not shown). GFP fluorescence was however observed in liver stage parasites in a structure resembling the apicoplast (Stanway \textit{et al.}, 2009), indicating that \textit{Pb} apiG3PAT is normally expressed at this stage (Supplementary Fig. 5). Apicoplast targeting of \textit{Pb} apiG3PAT was then confirmed by immunofluorescence microscopy and colocalization of the HA and GFP tags with the FASII enzyme FabI (Yu \textit{et al.}, 2008) (Fig. 4). This demonstrated that \textit{Pb} apiG3PAT is localized to the apicoplast and expressed in liver stage parasites, consistent with the observed up-regulation of FASII enzymes at this stage in rodent malaria models (Tarun \textit{et al.}, 2008).

\textit{Pb} apiG3PAT is dispensable in blood and mosquito stage parasites

Having shown that \textit{Pb} apiG3PAT was targeted to the apicoplast and expressed in liver stage parasites, we next sought to test whether it was essential for late liver stage development like \textit{Py} apiG3PAT (Lindner \textit{et al.}, 2014) and FASII (Yu \textit{et al.}, 2008; Vaughan \textit{et al.}, 2009) in rodent malaria models. For this, a double cross over homologous recombination strategy was used to disrupt \textit{Pb} apiG3PAT...
by inserting the hDHFR cassette into its coding sequence, mirroring the approach we used to disrupt Pf apiG3PAT (Supplementary Fig. 6). Drug-resistant parasites were obtained from two independent transfections and cloned by limiting dilution, and successful disruption of the Pb apiG3PAT locus in each clone was confirmed by PCR (Supplementary Fig. 6). The ability to recover Pb apiG3PAT (−) parasites indicated the enzyme was not essential in asexual blood stage parasites, consistent with the dispensability of Py apiG3PAT (Lindner et al., 2014) and FASII at this stage (Yu et al., 2008; Vaughan et al., 2009). Furthermore, comparison of the Pb apiG3PAT (−) clone 1 to wild type parasites in an in vivo blood stage growth assay revealed no apparent difference between the lines (Fig. 5A), confirming that as for Pf apiG3PAT, disruption of the P. berghei enzyme had no appreciable impact on growth at this stage.

Next, to determine whether disruption of Pb apiG3PAT altered parasite transmission or development in the mosquito, we compared the numbers of male gametocytes, ookinetes, oocysts and salivary gland sporozoites produced by Pb apiG3PAT (−) and wild type parasites. Preliminary experiments indicated that neither of the Pb apiG3PAT (−) clones displayed any defects in mosquito stage development, consistent with our inability to detect expression of Pb apiG3PAT by fluorescence microscopy at these stages. More detailed analysis of Pb apiG3PAT (−) clone 1 further confirmed that disruption of the enzyme had no appreciable impact on these stages, with the mean numbers of male gametocytes, ookinetes, oocysts or salivary gland sporozoites from five experiments closely approximating those observed for wild type (Fig. 5B). Disruption of Pb apiG3PAT therefore had no apparent impact on parasite transmission or development in the mosquito, consistent with the finding that neither Py apiG3PAT (Lindner et al., 2014) or FASII (Yu et al., 2008; Vaughan et al., 2009) is required in these life stages in rodent malaria models.

Pb apiG3PAT is required for normal sporozoite infectivity in vivo

After establishing that disruption of Pb apiG3PAT did not affect mosquito stage development, we sought to test whether Pb apiG3PAT (−) sporozoites differed from wild type in their ability to produce patent blood stage infections in vivo. To compare the infectivity of Pb apiG3PAT (−) and wild type, we intravenously injected sporozoites into outbred Swiss Webster mice, and time to blood stage patency was monitored. Preliminary experiments with the Pb apiG3PAT (−) clones indicated they were both markedly attenuated in infectivity relative to wild type (data not shown), consistent with the observed phenotype of the P. berghei FASII null mutants (Yu et al., 2008; Annoura et al., 2012; Nagel et al.,...
we then investigated whether the enzyme was required for
(data not shown). Focusing on
required for the initial establishment of liver stage infections
ability to invade hepatocytes, indicating the enzyme was not
invade and develop within HepG2 hepatocytes
the ability of
ment in the late liver stage. To investigate this, we compared
The reduction in
\( \text{Pb apiG3PAT (–)} \) sporozoite infectivity hinted that as for FASII (Yu et al., 2008; Vaughan et al.,
2009), the enzyme may be required for parasite development
in the late liver stage. To investigate this, we compared
\( \text{Pb apiG3PAT (–)} \) and wild type sporozoites to
invade and develop within HepG2 hepatocytes \( \text{in vitro} \). \( \text{Pb apiG3PAT (–)} \) and wild type sporozoites did not differ in their
ability to invade hepatocytes, indicating the enzyme was not
required for the initial establishment of liver stage infections
(data not shown). Focusing on \( \text{Pb apiG3PAT (–)} \) clone 1, we then investigated whether the enzyme was required for
the growth or development of liver stage parasites. First, to
investigate if disruption of \( \text{Pb apiG3PAT (–)} \) affected liver stage parasite growth, we performed immunofluorescence micros-
copy of \( \text{Pb apiG3PAT (–)} \) clone 1 and wild type at various
times post-infection using antibodies against the cytosolic
marker HSP70 and measured parasite cross-sectional area
as described (Schrader et al., 2013) in three independent
experiments. No difference in mean parasite size was
observed between \( \text{Pb apiG3PAT (–)} \) and wild type parasites
at 24 h post-infection, demonstrating the enzyme was not
required for parasite growth in the early liver stage (Fig.
6A). However, at 48 and 66 h post-infection, \( \text{Pb apiG3PAT (–)} \) parasites were significantly smaller than wild type as
determined by a two-tailed \( t \)-test, with mean areas 22% and
26% less than the control, respectively (Fig. 6B and C,
Supplementary Fig. 7). Disruption of \( \text{Pb apiG3PAT} \) therefore
negatively impacted the growth of parasites in the late liver
stage, consistent with the requirement for both \( \text{Py apiG3PAT} \)
(Lindner et al., 2014) and FASII for normal growth at this
stage in rodent malaria models (Yu et al., 2008; Vaughan
et al., 2009).

Next, to investigate whether disruption of \( \text{Pb apiG3PAT} \) affected the ability of late liver stage parasites to complete
development, we assessed their capacity to produce
detached cells and merozomes, which are the final liver
stage forms normally observed \( \text{in vitro} \) (Sturm et al., 2006).
To examine the formation of detached cells and
merosomes, we collected culture supernatants from hepato-
cytes at 66 and 72 h post-infection, stained briefly with
Hoechst nuclear stain, then counted these exoerythrocytic
forms by live fluorescence microscopy on three separate
occasions. Consistent with previous reports (Nagel et al.,
2013), wild type parasites produced the majority of detached
cells and merozomes at 66 h post-infection, with smaller
numbers of these forms detected at the 72 h (Fig. 6D). By
contrast, \( \text{Pb apiG3PAT (–)} \) clone 1 was never seen to
produce detached cells or merozomes at either 66 or 72 h.
Disruption of \( \text{Pb apiG3PAT} \) therefore severely compromised
the ability of parasites to complete liver stage development
\( \text{in vitro} \). This in turn suggested the reduced infectivity of \( \text{Pb apiG3PAT (–)} \) sporozoites resulted from defects in liver
stage merozoite production, although evidently a small

\[ \text{Table 1. Pb apiG3PAT (–) parasites show reduced sporozoite infectivity in vivo.} \]

| Strain            | Route            | Sporozoites | Fraction patent | Days to patencya |
|-------------------|------------------|-------------|-----------------|------------------|
| \( \text{Pb apiG3PAT (–)} \) | Intravenous      | 10 000      | 5/6             | 8.8              |
| Wild type         | Intravenous      | 10 000      | 6/6             | 4.2              |
| \( \text{Pb apiG3PAT (–)} \) | Intravenous      | 1000        | 1/6             | 10               |
| \( \text{Pb ANKA WT} \) | Intravenous      | 1000        | 4/6             | 5.8              |
| \( \text{Pb apiG3PAT (–)} \) | Mosquito bite    | 10 mosquitoes | 1/6             | 11               |
| \( \text{Pb ANKA WT} \) | Mosquito bite    | 10 mosquitoes | 6/6             | 4.5               |

n | Mean days to patency calculated from mice that developed a patent infection.
number of merozoites were still produced in vivo, consistent with reports for the Plasmodium berghei FASII null mutants (Yu et al., 2008; Nagel et al., 2013).

Pb apiG3PAT is required for normal apicoplast and nuclear development in the late liver stage, but is not critical for expression of merozoite surface protein 1

Having established that Pb apiG3PAT (−) parasites showed similar defects in late liver stage growth and maturation to FASII null mutants in rodent malaria models (Yu et al., 2008; Vaughan et al., 2009), we next tested whether disruption of the enzyme reproduced any of the other defects reported for these mutants (Pei et al., 2010; Annoura et al., 2012; Nagel et al., 2013). To explore whether disruption of Pb apiG3PAT similarly affected apicoplast and nuclear development in the late liver stage, we performed immunofluorescence microscopy of Pb apiG3PAT (−) clone 1 and wild type parasites with antibodies against ACP and DAPI nuclear stain at various time points post-infection. No difference was observed between Pb apiG3PAT (−) and wild type parasites at 24 h post-infection, demonstrating the enzyme was not required for apicoplast or nuclear development in the early liver stage (Fig. 7A). By contrast, Pb apiG3PAT (−) parasites had noticeably smaller apicoplasts and fewer nuclei than wild type at 48 and 66 h (Fig. 7B and C). Moreover, whereas wild type parasites had typically undergone schizogony and the apicoplast and nuclei had divided into daughter merozoites by 66 h, Pb apiG3PAT (−) parasites were never seen to progress to this stage. This further supported our finding that disruption of Pb apiG3PAT severely impacted liver stage merozoite production, and suggested that like FASII (Yu et al., 2008; Vaughan et al., 2009; Pei et al., 2010), the enzyme may be directly or indirectly required for apicoplast and nuclear development in the late liver stage.

Next, we investigated whether as in FASII null mutants in rodent models (Yu et al., 2008; Vaughan et al., 2009; Pei et al., 2010; Annoura et al., 2012; Nagel et al., 2013), disruption of Pb apiG3PAT affected the expression of MSP1 or its localization to the plasma membrane in late liver stage parasites. For this, we used immunofluorescence microscopy to localize MSP1 in Pb apiG3PAT (−) clone 1 and wild type parasites at 48 and 66 h post-infection. To enable the plasma membrane of early liver stage parasites to be examined, we also performed immunofluorescence microscopy of parasites at 24 h post-infection using antibodies against CSP as previously described (Lindner et al., 2014). No difference was observed between Pb apiG3PAT (−) and wild type in CSP staining at 24 h, confirming disruption of the enzyme did not impact parasite growth or plasma membrane morphology in the early liver stage (Fig. 8A). Surprisingly, we also failed to detect any perceivable difference in MSP1 staining at 48 h, with Pb apiG3PAT (−) parasites again appearing smaller than wild type, but nonetheless showing a diffuse pattern of MSP1 staining similar to the control (Fig. 8B). This indicated that...
although late liver stage growth was reduced in \( \text{Pb apiG3PAT} \) parasites, the expression and localization of MSP1 were not noticeably altered, contrasting with the phenotype reported for FASII null mutants (Yu et al., 2008; Vaughan et al., 2009; Pei et al., 2010; Annoura et al., 2012; Nagel et al., 2013). Consistent with our finding that loss of \( \text{Pb apiG3PAT} \) severely impaired merozoite production, we did observe differences between the lines at 66 h, with MSP1 staining typically detected around individual merozoites in the wild type, but remaining patchy or indicative of only limited plasma membrane invagination in \( \text{Pb apiG3PAT} \) parasites (Fig. 8C). This suggested that as for FASII in the rodent malaria models, \( \text{Pb apiG3PAT} \) was likely involved in synthesizing lipids for the developing merozoite membranes. However, as MSP1 staining was still readily detected in \( \text{Pb apiG3PAT} \) parasites, it again indicated that MSP1 expression was not impacted to the same extent as for the \( P. \) berghei FASII null mutants (Yu et al., 2008; Annoura et al., 2012).

To more quantitatively compare the proportions of MSP1-expressing parasites in the \( \text{Pb apiG3PAT} \) clone 1 and wild type lines, we performed immunofluorescence...
microscopy of late liver stage parasites using antibodies against both MSP1 and the parasitophorous vacuole marker UIS4 (Mueller et al., 2005). Using UIS4 staining to identify parasites, we scored the proportion that was MSP1-positive at 48 and 66 h in three independent experiments. Consistent with our observation using MSP1 antibodies alone, no significant difference was observed between Pf apiG3PAT (−) and wild type at 48 h, with over 75% of parasites scored as MSP1 positive in each line (Fig. 9, Supplementary Fig. 8). A modest but significant decrease was observed between Pf apiG3PAT (−) and wild type at 66 h, with the mean proportion of MSP1 positive parasites found to be 64% and 78%, respectively (Fig. 9, Supplementary Fig. 8). However, as this equated to only an 18% reduction relative to wild type, the MSP1 phenotype observed for Pf apiG3PAT (−) parasites was still far more mild than reported for the Pf apiG3PAT mutant in blood stage parasites, but severe defects observed for the Pf apiG3PAT mutant in lipid-depleted cultures indicate that the mild MSP1 phenotype observed for the Pf apiG3PAT mutant in the late liver stage.

Together, these findings extend upon previous research on the P. yoelii apicoplast G3PAT, and reveal new information about how pathways in both the apicoplast and ER contribute to incorporating FASII fatty acids into precursors for membrane lipids such as the MSP1 GPI anchor. We provide important confirmation that the requirement for FASII for late liver stage development in rodent malaria models likely reflects a need for fatty acids for membrane lipid production, and demonstrate that fatty acid synthesis and scavenging pathways can differ in their contribution to certain lipid species. As human and rodent malaria parasites differ in their requirement for FASII across the parasite life cycle, it is not yet clear how closely these findings will be echoed in P. falciparum. However, should future experiments reveal that FASII and Pf apiG3PAT are similarly...
required for the *P. falciparum* liver stage, we anticipate this information will help guide further research and assist in identifying the most strategic aspects of lipid metabolism to target for malaria prophylaxis.

**Experimental Procedures**

**Routine maintenance of *P. falciparum***

*P. falciparum* D10 wild type parasites and transgenic lines were maintained as previously described (Trager and Jensen, 1976) at 2% haematocrit in RPMI-HEPES supplemented with AlbuMAX II (Gibco) for all experiments unless otherwise stated.

**Generation and analysis of Pf apiG3PAT<sub>1–70</sub> gfp transgenic parasites**

The region encoding the predicted *Pf* apiG3PAT apicoplast targeting sequence was amplified from *P. falciparum* genomic DNA using primers P1 and P2 (Supplementary Table 1) and introduced into the pHBIR vector between the PfHSP86 promotor and GFP coding sequence as previously described (van Dooren et al., 2005). The resulting *Pf* apiG3PAT<sub>1–70</sub> gfp vector was transfected into ring stage parasites using the standard electroporation protocol (Wu et al., 1995; Crabb and Cowman, 1996). Parasites were then cultured in the presence of 2.5 μg ml<sup>−1</sup> blasticidin S (Invitrogen) to select for episomal maintenance of the vector.

Live microscopy of *Pf* apiG3PAT<sub>1–70</sub> gfp parasites was performed by staining cultures briefly with 1 μg ml<sup>−1</sup> 4’,6-diamidino-2-phenylindole (DAPI), before immobilizing cells in media on glass coverslips pre-treated with 0.1% polyethyleneimine. Images were acquired using a Leica SP2 inverted confocal microscope at ambient temperature, and merged and contrast adjusted using ImageJ software (NCBI).

Immunofluorescence microscopy of *Pf* apiG3PAT<sub>1–70</sub> gfp parasites was performed by fixing in paraformaldehyde/glutaraldehyde and permeabilizing in Triton X-100 as previously described (Tonkin et al., 2004) but without the sodium borohydride treatment step. Labelling was performed with mouse anti-GFP (Roche), rabbit anti-ACP (our laboratory (Waller et al., 2000)), Alexa Fluor goat anti-mouse-488 and Alexa Fluor goat anti-rabbit-546 (Molecular Probes). Samples were then stained with 1 μg ml<sup>−1</sup> DAPI and mounted in Fluorescence Mounting Medium (DAKO) before imaging as above.

**Bacterial complementation assay and mutagenesis of Pf apiG3PAT**

The *Pf* apiG3PAT coding sequence (without apicoplast targeting sequence) was amplified from *P. falciparum* genomic DNA using primers P3 and P4 (Supplementary Table 1) and introduced into the pQE-30 Xa vector (Qiagen), and cloned into the vector as above. Vectors were transformed into the *E. coli* plsB26 mutant alongside the pREP4 co-vector (Qiagen), and clones were selected and grown under permissive conditions to allow all isolates to be propagated. To assess for complementation, equivalent cell numbers were transferred to non-permissive M56LP media without glycerol (Bell, 1974), then growth at 37°C was assessed by monitoring optical density at 600 nm. All assays were performed in duplicate on different days using independently isolated colonies, with two technical replicates for each time point.

Western blot analysis of transformed bacteria was performed by growing isolated clones under permissive conditions, pelleting cells by centrifugation, then lysing by freeze/thawing and boiling in SDS loading buffer. Proteins were separated by SDS-PAGE and transferred to nitrocellulose, then membranes were probed using mouse anti-hexahistidine (Thermo Scientific) and goat anti-mouse-horseradish peroxidase (Thermo Scientific). Protein bands were detected using ECL Western Blotting Substrate (Pierce) and images were acquired using a BioRad ChemiDoc Imager.

Site directed mutagenesis of the *Pf* apiG3PAT ‘HX<sub>D</sub>′ motif was performed by Mutagenex Inc., and activity of the mutated versions of the protein assessed by repeating the bacterial transformation, complementation assay and Western blot analysis as above.

**Generation and analysis of Pf apiG3PAT (–) parasites**

Two regions of the *Pf* apiG3PAT coding sequence were amplified from *P. falciparum* genomic DNA using primers P7, P8, P9 and P10 (Supplementary Table 1) and introduced into the pCC-1 transfection vector (Maier et al., 2008). The resulting vector was transfected into ring stage parasites using the standard electroporation protocol (Wu et al., 1995; Crabb and Cowman, 1996), then selection was performed with 5 nM WR99210 (Jacobus Pharmaceuticals) and 1 μM 5-fluorocytosine (Sigma) as previously described (Maier et al., 2006). Disruption of the *Pf* apiG3PAT locus in the two independently derived parasite populations was confirmed by PCR using primers P11, P12 and P13, with primers T1 and T2 used as controls (Supplementary Table 1).

Modification of the *Pf* apiG3PAT locus in the principal line examined in this study was additionally confirmed by whole genome sequencing as previously described (Straimer et al., 2012). Briefly, PCR-free libraries were prepared using NEBNext DNA Library reagents (NEB) and NEXTflex DNA Barcodes (Bio Scientific). Eight libraries were multiplexed with 8% PhiX control and run across two lanes on the Illumina HiSeq 2500 system using single-end sequencing. Sequencing data was analysed using Galaxy (Giardine et al., 2005; Blankenberg et al., 2010; Goecks et al., 2010). Reads were mapped to the *P. falciparum* 3D7v.10.0
Plasmodium falciparum and P. berghei apicoplast glycerol 3-phosphate acyltransferase 13 of 17

was performed as previously described (MacRae et al., 2009). Variants were called using Freebayes (Garrison and Marth, 2012), filtered for quality and read depth with GATK tools (Auwera et al., 2013) (Quality > 500, Read Depth > 75), and annotated using SnEff (Cingolani et al., 2012) (PF3D7v9.1 genome).

Immunofluorescence microscopy of parasites was performed using anti-ACP, Alexa Fluor goat anti-rabbit secondary antibodies and DAPI as above. Transmission electron microscopy was performed with trophozoite stage parasites previously described (Sturm et al., 2012). Briefly, infected RBCs were isolated using MACS magnetic separation columns (Miltenyi Biotec) and fixed in 2.5% glutaraldehyde in cacodylate buffer, then treated with 2% osmium tetroxide and 1.5% potassium ferrocyanide followed by 1% thioctic acid. Samples were further stained with 2% uranyl acetate and Walton’s lead aspartate before embedding in Procure 812 resin. Sections of approximately 70–100 nm were then cut and imaged using a Philips CM120 BioTWIN Transmission Electron Microscope and Gatan Multiscan Model 971 digital camera.

Blood stage growth assays in standard media were performed by monitoring the replication of synchronous parasites over two asexual cycles as previously described (Mitamura et al., 2000; Mi-Ichi et al., 2006). Prior to the assay, parasites were synchronized by two treatments with 5% sorbitol, and then allowed to mature into trophozoites before being transferred to assay dishes. Media was replaced daily, and parasitemia monitored by thin Giemsa-stained blood smears. Growth assays in lipid-depleted media were performed by synchronizing parasites as above, then washing parasites before transferring to lipid-depleted media to initiate the assay. Lipid-depleted media was prepared as previously reported (Botté et al., 2013) by replacing the lipid-rich AlbuMAX II component of standard media with an equivalent amount of fatty acid free bovine serum albumin (Sigma) and 30 μM palmitic acid (C16:0; Sigma) and 45 μM oleic acid (C18:1; Sigma). All assays were performed in triplicate on different days, and with a minimum of 400 RBCs counted per line time point.

Fatty acid profiling of magnetically isolated infected RBCs was performed as previously described (MacRae et al., 2014) with minor modifications. Briefly, cultures were pelleted by centrifugation and metabolism was quenched by immersion in dry ice/methanol slurry. Infected red blood cells were isolated using MACS magnetic separation columns (Miltenyi Biotec) at 4°C, before lipids were extracted from 1.0 to 2.0 × 10⁶ cells using chloroform:methanol (2:1 v/v, spiked with 25 nmoL lauric acid as an internal standard) by periodic sonication for 1 h in a refrigerated cold room. Samples were then centrifuged, and supernatants transferred to new tubes and dried under nitrogen. Pellets were re-extracted using methanol:water (2:1 v/v), and the second supernatants were then combined with the first extract and dried then stored at −80°C. Prior to GC-MS, extracts were partitioned into chloroform:methanol:water (1:3:3 v/v) and the apolar (lipid) phase was dried, derivatized to fatty acid methyl esters and analysed on an Agilent 7890B-5977A GC-MS system using a DB-5MS-DG column as previously described (MacRae et al., 2012). Data analysis was performed using MassHunter (Agilent) and fatty acid species were identified and quantified by comparison to authentic standards. Experiments were repeated with four biological replicates, and statistical significance between mean fatty acid abundances evaluated by t-test with correction for multiple testing using Prism v 6.02 (GraphPad).

Experimental animals and routine maintenance of P. berghei

Swiss Webster mice of four to six weeks of age were used for all experiments, and were sourced from the University of Melbourne Zoology Animal Facility or Monash University Animal Research Platform. All experiments were conducted in accordance with the local Prevention of Cruelty to Animals legislation and the University of Melbourne Animal Ethics Committee guidelines under ethics permits 1112043.1 and 1413078.

Mice were infected with P. berghei ANKA wild type or transgenic parasite lines by intraperitoneal injection, and parasitemia was monitored by thin Giemsa-stained smears. Numbers of male gametocytes were assessed by monitoring exflagellation as described (Sturm et al., 2015), and mice were deemed suitable for mosquito infection when ≥3 exflagellation events per 1000 RBCs were observed. Adult female Anopheles stephensi mosquitoes aged 3 to 7 days were infected by feeding on parasitized mice until engorged. Mosquitoes were maintained on 10% sucrose at 27°C and 80% humidity, and naive mice were infected after 21 days by biting or intravenous injection of sporozoites into the tail vein.

Infection of HepG2 cells with P. berghei sporozoites

HepG2 cells were grown at 37°C and 5% carbon dioxide in Advanced MEM medium (Gibco) containing 10% heat-inactivated fetal bovine serum, 2 mM GlutaMAX (Gibco), 1% penicillin/streptomycin (Hyclone) and a variable concentration of amphotericin B (Hyclone). Cells were seeded onto glass coverslips in 24-well plates or glass-bottomed culture dishes pre-treated with rat tail collagen type I (Sigma), and allowed to grow overnight before infection with sporozoites. Media was then changed 1–2 h after infection and twice daily thereafter for all experiments.

Generation and analysis of Pb apiG3P AT ha gfp parasites

The Pb apiG3PAT coding sequence (minus stop codon) was amplified from P. berghei genomic DNA using primers P14 and P15 and introduced into the pREP3 transfection vector, which was derived from the pL0006 vector (Malaria...
Research and Reference Reagent Resource Center) by addition of the GFP coding sequence downstream of the multiple cloning site. The resulting vector was linearized by cutting with BstEII, then transfected into schizont stage parasites using the Nucleofector device (Lonza) as previously described (Janse et al., 2006). Pyrimethamine-resistant parasites were recovered and clonal lines obtained by limiting dilution in 10 mice. The correct integration of the vector into the Pb apiG3PAT locus was confirmed by PCR using primers P16, P17 and P18, with primers T1 and T2 used as controls (Supplementary Table 1).

Live imaging of liver stage parasites was performed 48 h post-infection. Cells were stained briefly with 5 μg ml⁻¹ Hoechst 33342 (Life Technologies), then imaged using a Leica SP5 inverted laser scanning confocal microscope in a 37 C temperature controlled chamber. Images were taken sequentially for the two channels and processed using ImageJ software (NCBI).

Immunofluorescence microscopy of liver stage parasites was performed 48 post-infection. Cells were washed in PBS, fixed in 4% paraformaldehyde, washed again and permeabilized in 0.15% Triton X-100 before blocking in 3% bovine serum albumin. Labelling was performed with mouse anti-GFP (Roche), rabbit anti-Fab1 (gift from David Fidock; used as anti-ACP antibodies were temporarily unavailable), Alexa Fluor goat anti-mouse-488 and anti-rabbit-546 secondary antibodies (Molecular Probes). Samples were then stained with 1 μg ml⁻¹ DAPI, mounted in Fluorescence Mounting Medium (DAKO), and imaged using a Leica SP5 at ambient temperature as above.

Generation and analysis of Pb apiG3PAT (−) parasites

Regions of the Pb apiG3PAT coding sequence and 3’ UTR were amplified from P. berghei genomic DNA using primers P19, P20, P21 and P22 (Supplementary Table 1) and introduced into the pl0006 vector (Malaria Research and Reference Reagent Resource Center). The vector was linearized with SacII and Apal, then transfected into parasites and clonal lines obtained by limiting dilution as above. The correct integration of the vector into the Pb apiG3PAT locus was confirmed by PCR using primers P16, P17 and P23, with primers T1 and T2 used as controls (Supplementary Table 1).

Blood stage parasite growth assays were performed as previously described (Sturm et al., 2015) by intravenously injecting three sets of two mice with 1.0 × 10⁵ infected RBCs, then monitoring parasitemia daily by thin Giemsa-stained smears. Male gametocyte and mosquito stage development of parasites were assessed by determining the mean exflagellation rate and mean number of oocinetes, oocysts and salivary gland sporozoites for five separate infections. Exflagellation rate was determined as previously described (Sturm et al., 2015), then mosquito cages were infected and 10 individuals sacrificed at each time point. For oocinetes, blood boluses were isolated from mosquitoes 20–22 h post-infection, pooled and stained with mouse anti-p28 (gift from Robert Sinden) and goat anti-mouse Alexa Fluor 488 (Molecular Probes), then parasites were counted as described (Sturm et al., 2015) on a haemocytometer using an Olympus IX73 epifluorescence microscope. For oocysts, midguts were isolated from mosquitoes 14–15 days post-infection, stained with 2% Mercurochrome (Sigma), then viewed using an Olympus BH-2 light microscope. For sporozoites, salivary glands were isolated 21–22 days post-infection, disrupted in PBS, and then parasites were counted on a haemocytometer using an Olympus CK2 microscope.

Sporozoite infectivity in vivo was assessed by measuring the time to patency following intravenous injection of 1000 or 10 000 sporozoites or exposure to 10 infected mosquitoes for ten minutes. Parasitemia was monitored on days 3–14 post-infection by thin Giemsa-stained smears as described (Nagel et al., 2013). Smears were viewed using an Olympus BH-2 light microscope with 40× oil objective, and patency was judged by scanning a minimum of 20 adjacent fields of view as previously reported (Lindner et al., 2014).

Live stage parasite size was measured by performing immunofluorescence microscopy of parasites at 24, 48 and 66 h post-infection. Cells were fixed as above and labelled with mouse anti-HSP70 (gift from Moriya Tsuji), goat anti-mouse Alexa Fluor 488 (Molecular Probes) and DAPI, before mounting in Fluorescence Mounting Medium (DAKO). Imaging was performed using an OMX V4 Blaze in wide field deconvolution mode, with z-slices acquired across the entire depth of the parasites. Image deconvolution and maximum projection were performed using softWORx software (Applied Precision), and parasite cross-sectional areas calculated using ImageJ (NCBI). Experiments were repeated three times with >50 parasites imaged per replicate, and statistical analysis was performed using Prism version 6.0 (GraphPad).

Detached cell and merosome formation by parasites was assessed by collecting culture supernatants 66 and 72 h post-infection. Cells were stained briefly with 5 μg ml⁻¹ Hoechst 33342 (Life Technologies), the counted using the Leica SP2 inverted microscope in epifluorescence mode. Experiments were repeated three times, with a minimum of four wells counted on each occasion.

Immunofluorescence microscopy of liver stage parasites to examine apicoplast and plasma membrane morphology was performed by fixing and labelling with rabbit anti-ACP, mouse anti-CSP (gift from Louis Schofield) or mouse anti-MSP1 (gift from Paul Gilson), then with Alexa Fluor secondary antibodies and DAPI before mounting as above. Images were acquired with a Leica SP2 inverted microscope in epifluorescence mode and processed using ImageJ (NCBI).

Immunofluorescent microscopy of liver stage parasites to quantify MSP1 staining was performed by fixing and staining with mouse anti-UIS4 (gift from Photini Sinnis) and anti-MSP1 antibodies, then with secondary antibodies and DAPI before mounting and imaging as above. Experiments were performed...
repeated three times with >100 parasites counted per replicate, and statistical analysis was performed using Prism version 6.0 (GraphPad).

Acknowledgements

MJS was supported by an Australian Postgraduate Award. GIM gratefully acknowledges a Program Grant from the National Health and Medical Research Council (Australia) and a Discovery Grant from the Australian Research Council. CYB was supported by ANR-RPDOC/Atip-Avenir CNRS/Fnovo Grant/Labex Parafregt grants (Apicolid projects) and a FP7 Marie Curie Actions International Outgoing Fellowship. ML was funded through generous support from the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease Award (1007041.01) and start-up funding from The Pennsylvania State University. We also thank the Australian Red Cross for blood.

References

Aly, A.S.I., Vaughan, A.M., and Kappe, S.H.I. (2009) Malaria parasite vaccine candidates. *Vaccine* 30: 2662–2670.

Auwera, G.A., Carneiro, M.O., Hartl, C., Poplin, R., del Angel, G., Levy Moonshine, A., et al. (2013) From FastQ Data to High-Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline. Hoboken, NJ, USA: John Wiley & Sons.

Bell, R.M. (1974) Mutants of *Escherichia coli* defective in membrane phospholipid synthesis: macromolecular synthesis in an sn-glycerol 3-phosphate acyltransferase Km mutant. *J Bacteriol* 117: 1065–1076.

Blankenberg, D., Kuster, G.V., Coraor, N., Ananda, G., Lazarus, R., Mangan, M., et al. (2010) Galaxy: A Web-Based Genome Analysis Tool for Experimentalists. Hoboken, NJ, USA: John Wiley & Sons, Inc.

Bott, C.Y., Yamayo-Botté, Y., Rupasinghe, T.W.T., Mullin, K.A., MacRae, J.L., Spurck, T.P., et al. (2013) Atypical lipid composition in the purified relict plastid (apicoplast) of malaria parasites. *Proc Natl Acad Sci U S A* 110: 7506–7511.

Bozdech, Z., Llinás, M., Pulliam, B.L., Wong, E.D., Zhu, J., and DeRisi, J.L. (2003) The transcriptome of the intraerythrocytic developmental cycle of *Plasmodium falciparum*. *PLoS Biol* 1: e5.

Butler, N.S., Schmidt, N.W., Vaughan, A.M., Aly, A.S., Kappe, S.H.I., and Harty, J.T. (2011) Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. *Cell Host Microbe* 9: 451–462.

Cingolani, P., Patel, V.M., Coon, M., Nguyen, T., Land, S.J., Ruden, D.M., and Lu, X. (2012) Using *Drosophila melanogaster* as a model for genotoxic chemical mutational studies with a new program, SnpSift. *Front Genet* 3: 35. doi: 10.3389/fgene.2012.00035.

Crabb, B.S., and Cowman, A.F. (1996) Characterization of promoters and stable transfection by homologous and nonhomologous recombination in *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* 93: 7289–7294.
Llinás, M. (2006) Comparative whole genome transcriptome analysis of three Plasmodium falciparum strains. Nucleic Acids Res 34: 1166–1173.

MacRae, J.I., Lopaticki, S., Maier, A.G., Rupasinghe, T., Nahid, A., Cowman, A.F., and McConville, M.J. (2014) Plasmodium falciparum is dependent on de novo myo-inositol biosynthesis for assembly of GPI glycolipids and infectivity. Mol Microbiol 91: 762–776.

MacRae, J.I., Sheiner, L., Nahid, A., Tonkin, C., Striepen, B., and McConville, M.J. (2012) Mitochondrial metabolism of glucose and glutamine is required for intracellular growth of Toxoplasma gondii. Cell Host Microbe 12: 682–692.

Maier, A.G., Braks, J.A.M., Waters, A.P., and Cowman, A.F. (2006) Negative selection using yeast cytosine deaminase/uracil phosphoribosyl transferase in Plasmodium falciparum for targeted gene deletion by double crossover recombination. Mol Biochem Parasitol 150: 118–121.

Maier, A.G., Rug, M., O’Neill, M.T., Brown, M., Chakravorty, S., Szestak, T., et al. (2008) Exported proteins required for virulence and rigidity of Plasmodium falciparum-infected human erythrocytes. Cell 134: 48–61.

Mi-Ichi, F., Kita, K., and Mitamura, T. (2006) Intraerythrocytic parasitism of Plasmodium falciparum utilizes a broad range of serum-derived fatty acids with limited modification for their growth. Parasitology 133: 399–410.

Mitamura, T., Hanada, K., Ko-Mitamura, E.P., Nishijima, M., and Horii, T. (2000) Serum factors governing intraerythrocytic development and cell cycle progression of Plasmodium falciparum. Parasitol Int 49: 219–229.

Mueller, A.-K., Camargo, N., Kaiser, K., Andorfer, C., Frevert, U., Matuschewski, K., and Kappe, S.H.I. (2005) Plasmodium liver stage developmental arrest by deletion of a protein at the parasite–host interface. Proc Natl Acad Sci U S A 102: 3022–3027.

Nagel, A., Prado, M., Heitmann, A., Tartz, S., Jacobs, T., Deschermeier, C., et al. (2013) A new approach to generate a safe double-attenuated Plasmodium liver stage vaccine. Int J Parasitol 43: 503–514.

Pei, Y., Tarun, A.S., Vaughan, A.M., Herman, R.W., Soliman, J. M. B., Erickson-Wayman, A., and Kappe, S.H.I. (2010) Plasmodium pyruvate dehydrogenase activity is only essential for the parasite’s progression from liver infection to blood infection. Mol Microbiol 75: 957–971.

Petersen, T.N., Brunak, S., von Heijne, G., and Nielsen, H. (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 8: 785–786.

Ralph, S.A., van Dooren, G.G., Waller, R.F., Crawford, M.J., Fraunholz, M.J., Foth, B.J., et al. (2004) Metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat Rev Micro 2: 203–216.

Santiago, T.C., Zufferey, R., Mehra, R.S., Coleman, R.A., and Mamoun, O.B. (2004) The Plasmodium falciparum PfGatp is an endoplasmic reticulum membrane protein important for the initial step of malarial glycerolipid synthesis. J Biol Chem 279: 9222–9232.

Schartl, L.F., Wirtz, R.A., and Azad, A.F. (1994) Susceptibility of different strains of mice to hepatic infection with Plasmodium berghei. Infect Immun 62: 4844–4847.

Schneider, S.C., Linco, G., Salett, J.M., Dahse, H.-M., Afanador, G.A., Prigge, S.T., et al. (2013) Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents. ChemMedChem 8: 442–461.

Shears, M.J., Botté, C.Y., and McFadden, G.I. (2015) Fatty acid metabolism in the Plasmodium apicoplast: drugs, doubts and knockouts. Mol Biochem Parasitol 199: 34–50.

Stanway, R.R., Witt, T., Zobiak, B., Aepfelbacher, M., and Heussler, V.T. (2009) GFP-targeting allows visualization of the apicoplast throughout the life cycle of live malaria parasites. Biol Cell 101: 415–435.

Sturm, J., and Müller, S. (2012) Lipoic acid metabolism of Plasmodium – a suitable drug target. Curr Pharm Des 18: 3480–3489.

Stratmann, J., Lee, M.C.S., Lee, A.H., Zeitler, B., Williams, A.E., Pearl, J.R., et al. (2012) Site-specific genome editing in Plasmodium falciparum using engineered zinc-finger nucleases. Nat Methods 9: 993–998.

Sturm, A., Amino, R., van de Sand, C., Regen, T., Retzlaff, S., Rennenberg, A., et al. (2006) Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 313: 1287–1290.

Sturm, A., Molland, V., Cozijnsen, A., Goodman, C.D., and McFadden, G.I. (2015) Mitochondrial ATP synthase is dispensable in blood-stage Plasmodium berghei rodent malaria but essential in the mosquito stage. Proc Natl Acad Sci U S A 112: 10216–10223.

Tamada, T., Feese, M.D., Ferri, S.R., Kato, Y., Yajima, R., Toguri, T., and Kuroki, R. (2004) Substrate recognition and selectivity of plant glycerol-3-phosphate acyltransferases (GPATs) from Cucurbita moschata and Spinacea oleracea. Acta Crystallogr D Biol Crystallogr 60: 13–21.

Tarun, A.S., Peng, X., Dumpit, R.F., Ogata, Y., Silva-Rivera, H., Camargo, N., et al. (2008) A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci U S A 105: 305–310.

Tarun, A.S., Vaughan, A.M., and Kappe, S.H.I. (2009) Redefining the role of de novo fatty acid synthesis in Plasmodium parasites. Trends Parasitol 25: 545–550.

Tonkin, C.J., van Dooren, G.G., Spurck, T.P., Struck, N.S., Good, R.T., Handman, E., et al. (2004) Localization of organellar proteins in Plasmodium falciparum using a novel set of transfection vectors and a new immunofluorescence fixation method. Mol Biochem Parasitol 137: 13–21.

Trager, W., and Jensen, J.B. (1976) Human malaria parasites in continuous culture. Science 193: 673–675.

Tumbull, A.P., Rafferty, J.B., Sedelnikova, S.E., Slabas, A.R., Schierer, T.P., Kroon, J., et al. (2001) Analysis of the structure, substrate specificity, and mechanism of squash glycerol-3-phosphate (1)-acyltransferase. Structure 9: 347–353.

van Dooren, G.G., and Striepen, B. (2013) The algal past and present of the apicoplast. Annu Rev Microbiol 67: 271–289.

van Dooren, G.G., Marti, M., Tonkin, C.J., Stimmmer, L.M., Cowman, A.F., and McFadden, G.I. (2005) Development of the endoplasmic reticulum, mitochondrion and apicoplast during the asexual life cycle of Plasmodium falciparum. Mol Microbiol 57: 405–419.

van Schaijk, B.C.L., Kumar, T.R.S., Vos, M.W., Richman, A., van Gemert, G.J., Li, T., et al. (2014) Type II fatty acid biosynthesis is essential for Plasmodium falciparum sporozoite development in the midgut of Anopheles mosquitoes. Eukaryot Cell 13: 550–559.
Vaughan, A.M., O'Neill, M.T., Tarun, A.S., Camargo, N., Phuong, T.M., Aly, A.S.I., et al. (2009) Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. *Cell Microbiol* 11: 506–520.

Waller, R.F., Keeling, P.J., Donald, R.G., Striepen, B., Handman, E., Lang-Unnasch, N., et al. (1998) Nuclear-encoded proteins target to the plastid in *Toxoplasma gondii* and *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* 95: 12352–12357.

Waller, R.F., Reed, M.B., Cowman, A.F., and McFadden, G.I. (2000) Protein trafficking to the plastid of *Plasmodium falciparum* is via the secretory pathway. *EMBO J* 19: 1794–1802.

Wu, Y., Sifri, C.D., Lei, H.-H., Su, X.-Z., and Wellems, T.E. (1995) Transfection of *Plasmodium falciparum* within human red blood cells. *Proc Natl Acad Sci U S A* 92: 973–977.

Yu, M., Kumar, T.R.S., Nkrumah, L.J., Coppi, A., Retzlaff, S., Li, C.D., et al. (2008) The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. *Cell Host Microbe* 3: 567–578.

Zuegge, J., Ralph, S., Schmuker, M., McFadden, G.I., and Schneider, G. (2001) Deciphering apicoplast targeting signals – feature extraction from nuclear-encoded precursors of *Plasmodium falciparum* apicoplast proteins. *Gene* 280: 19–26.

Supporting information

Additional supporting information may be found in the online version of this article at the publisher's web-site:

**Table S1.** Primers used in this study.

**Table S2.** Mean relative fatty acid abundance in total lipid extracts from infected RBCs isolated from cultures of *Pf apiG3PAT* (−) or wild type parasites.

**Fig. S1.** Alignment of *Pf apiG3PAT* and *Pb apiG3PAT* showing the predicted apicoplast targeting sequence and ‘HX4D’ motif characteristic of glycerol 3-phosphate acyltransferases.

**Fig. S2.** Generation of *Pf apiG3PAT* (−) parasites.

**Fig. S3.** Disruption of *Pf apiG3PAT* does not affect blood stage cell cycle progression on standard or lipid-depleted media.

**Fig. S4.** *Pb apiG3PAT* tagging strategy and confirmation by PCR.

**Fig. S5.** Live fluorescence microscopy of *Pb apiG3PAT* ha gfp liver stage parasites.

**Fig. S6.** *Pb apiG3PAT* knockout strategy and confirmation by PCR.

**Fig. S7.** Representative immunofluorescence images of *Pb apiG3PAT* (−) and wild type parasites as used for measuring liver stage cell size.

**Fig. S8.** Representative immunofluorescence images of *Pb apiG3PAT* (−) and wild type parasites as stained for scoring expression of merozoite surface protein 1 (MSP1) in the late liver stage.
